

Satoshi Tamaru

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3812734/satoshi-tamaru-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18
papers

54
citations

5
h-index

7
g-index

22
ext. papers

77
ext. citations

2.6
avg, IF

0.81
L-index

#	Paper	IF	Citations
18	Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer.. <i>Case Reports in Oncological Medicine</i> , 2022 , 2022, 2709062	0.9	1
17	Long-term follow-up results of a phase II study of dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7551-7551	2.2	
16	Efficacy of a small-caliber colonoscope for pain in female patients during unsedated colonoscopy: a randomized controlled study. <i>Endoscopy International Open</i> , 2021 , 9, E1055-E1061	3	0
15	Improving the Prognosis of Pancreatic Cancer Through Early Detection: Protocol for a Prospective Observational Study. <i>JMIR Research Protocols</i> , 2021 , 10, e26898	2	0
14	DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. <i>Haematologica</i> , 2020 , 105, 2308-2315	6.6	14
13	Safety Evaluation of Tadalafil Treatment for Fetuses with Early-Onset Growth Restriction (TADAFER): Results from the Phase II Trial. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	8
12	Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy. <i>Clinical Breast Cancer</i> , 2018 , 18, e157-e165	3	3
11	Dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL): Primary analysis of PEARL5 study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7561-7561	2.2	1
10	Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers. <i>Oncotarget</i> , 2018 , 9, 14909-14921	2.3	6
9	TADAFER II: Tadalafil treatment for fetal growth restriction - a study protocol for a multicenter randomised controlled phase II trial. <i>BMJ Open</i> , 2018 , 8, e020948	3	5
8	Successful treatment by prednisolone for interstitial pneumonia associated with anagrelide in a patient with essential thrombocythemia. <i>International Cancer Conference Journal</i> , 2017 , 6, 22-24	0.9	1
7	Efficacy of transdermal scopolamine for sialorrhea in patients with amyotrophic lateral sclerosis. <i>Cogent Medicine</i> , 2017 , 4, 1365401	1.4	6
6	Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension. <i>Journal of Clinical Hypertension</i> , 2017 , 19, 990-998	2.3	3
5	Colon cancer chemotherapy for a patient with CDX2-expressing metastatic thymic adenocarcinoma: a case report and literature review. <i>International Cancer Conference Journal</i> , 2016 , 5, 113-119	0.9	
4	Dose-Adjusted (DA) - EPOCH-R with High-Dose Methotrexate for Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma (CD5+ DLBCL): Interim Results from a Phase II Study. <i>Blood</i> , 2016 , 128, 3029-3029	2.2	
3	Difference in survival and prognostic factors between smokers and never-smokers with advanced non-small-cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2013 , 18, 17-25	4.2	4
2	Correlation between low-dose cyclophosphamide-induced hyponatraemia and the use of aprepitant.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e19546-e19546	2.2	

- 1 Calyculin A retraction of mature megakaryocytes proplatelets from embryonic stem cells. *Biochemical and Biophysical Research Communications*, **2008**, 366, 763-8 3.4 1